James F. Chmiel, MD

Faculty

James F. Chmiel, MD

Professor of Pediatrics

Email ooarhe@iu.edu

Phone 317-948-7208

Address

705 Riley Hospital Drive
ROC 4270

Indianapolis, IN 46202

Bio

Dr. James Chmiel is the Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine and a Professor of Professor Pediatrics at Indiana University School of Medicine. He is a graduate of University of Michigan Medical School. Dr. Chmiel completed his pediatric residency at Children’s Memorial Hospital/Northwestern University Medical School and pediatric pulmonology fellowship at Case Western University School of Medicine/Rainbow Babies and Children’s Hospital. Dr. Chmiel holds membership in numerous national professional societies including the American Thoracic Society, Society for Pediatric Research, and the American Pediatric Society. His Research focuses on airway inflammation particularly as it relates to cystic fibrosis and asthma.

Titles & Appointments

Professor of Pediatrics
Division Chief, Pediatric Pulmonology, Allergy and Sleep Medicine

Education

1999 FEL Pediatric Pulmonology Fellowship, Case Western Reserve University School of Medicine

1994 RES Pediatric Residency, Northwestern University Medical School

1991 MD University of Michigan

1991 MPH University of Michigan

1986 BS University of Notre Dame
Research

Early in his career, Dr. Chmiel did primarily basic science and translational research using the mouse agarose bead model to study the airway inflammatory response and the impact of exogenous anti-inflammatory therapies on it. Over that last several years, he has transitioned to a career in clinical research. His research involves understanding the inflammatory response of the lung, particularly as it relates to asthma and CF and the impact of anti-inflammatory therapeutics upon this response. He participates in both independent and multi-center clinical trials. In addition, Dr. Chmiel is interested in evaluating outcome measures for clinical trials in CF. He has been the lead PI on several multi-center studies sponsored by the Cystic Fibrosis Foundation’s Therapeutic Development Network (TDN) and participated in several NIH asthma networks including the Inner City Asthma Consortium, AsthmaNet, and SARP 3. Currently, Dr. Chmiel is the Chair the CF Foundation’s Anti-inflammatory Strategic Planning Committee and a member of its Clinical Research Committee. The ultimate goal of all of Dr. Chmiel’s research is to provide better care for patients with CF and asthma.
Publications

Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations.
Jackson DJ; Bacharier LB; Mauger DT; Boehmer S; Beigelman A; Chmiel JF; Fitzpatrick AM; Gaffin JM; Morgan WJ; Peters SP; Phipatanakul W; Sheehan WJ; Cabana MD; Holguin F; Martinez FD; Pongracic JA; Baxi SN; Benson M; Blake K; Covar R; Gentile DA; Israel E; Krishnan JA; Kumar HV; Lang JE; Lazarus SC; Lima JJ; Long D; Ly N; Marbin J; Moy JN; Myers RE; Olin JT; Raissy HH; Robison RG; Ross K; Sorkness CA; Lemanske RF Jr; National Heart, Lung, and Blood Institute AsthmaNet.; The New England journal of medicine 2018 Mar 3

Inflammation in cystic fibrosis: An update.
Roesch EA; Nichols DP; Chmiel JF; Pediatric pulmonology 2018 Jul 12

Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.
Polineni D; Dang H; Gallins PJ; Jones LC; Pace RG; Stonebraker JR; Commander LA; Krenicky JE; Zhou YH; Corvol H; Cutting GR; Drumm ML; Strug LJ; Boyle MP; Durie PR; Chmiel JF; Zou F; Wright FA; O'Neal WK; Knowles MR; American journal of respiratory and critical care medicine 2018 Jan 1

The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis.
Tangpricha V; Smith EM; Binongo J; Judd SE; Ziegler TR; Walker S; Tirouvanziam R; Zughaier SM; Lee MJ; Chesdachai S; Hermes WA; Chmiel JF; Gaggar A; Grossmann RE; Joseph PM; Alvarez JA; Contemporary clinical trials communications 2017 Mar 9

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
Jain R; Beckett VV; Konstan MW; Accurso FJ; Burns JL; Mayer-Hamblett N; Milla C; VanDevanter DR; Chmiel JF; KB001-A Study Group.; Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017 Dec 29

Neutrophils from F508del cystic fibrosis patients produce IL-17A and express IL-23 - dependent IL-17RC.
Taylor PR; Bonfield TL; Chmiel JF; Pearlman E; Clinical immunology (Orlando, Fla.) 2016 May 4

Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
Nichols DP; Happoldt CL; Bratcher PE; Caceres SM; Chmiel JF; Malcolm KC; Saavedra MT; Saiman L; Taylor-Cousar JL; Nick JA; Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2016 Dec 24

Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma.
Sheehan WJ; Mauger DT; Paul IM; Moy JN; Boehmer SJ; Szefler SJ; Fitzpatrick AM; Jackson DJ; Bacharier LB; Cabana MD; Covar R; Holguin F; Lemanske RF Jr; Martinez FD; Pongracic JA; Beigelman A; Baxi SN; Benson M; Blake K; Chmiel JF; Daines CL; Daines MO; Gaffin JM; Gentile DA; Gower WA; Israel E; Kumar HV; Lang JE; Lazarus SC; Lima JJ; Ly N; Marbin J; Morgan WJ; Myers RE; Olin JT; Peters SP; Raissy HH; Robison RG; Ross K; Sorkness CA; Thyne SM; Wechsler ME; Phipatanakul W; NIH/NHLBI AsthmaNet.; The New England journal of medicine 2016 Aug 18

Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.
Torphy TJ; Allen J; Cantin AM; Konstan MW; Accurso FJ; Joseloff E; Ratjen FA; Chmiel JF; Antiinflammatory Therapy Working Group.; Annals of the American Thoracic Society 2015 Sep

Inflammation and its genesis in cystic fibrosis.
Nichols DP; Chmiel JF; Pediatric pulmonology 2015 Oct

Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial.
Bacharier LB; Guilbert TW; Mauger DT; Boehmer S; Beigelman A; Fitzpatrick AM; Jackson DJ; Baxi SN; Benson M; Burnham CD; Cabana M; Castro M; Chmiel JF; Covar R; Daines M; Gaffin JM; Gentile DA; Holguin F; Israel E; Kelly HW; Lazarus SC; Lemanske RF Jr; Ly N; Meade K; Morgan W; Moy J; Olin T; Peters SP; Phipatanakul W; Pongracic JA; Raissy HH; Ross K; Sheehan WJ; Sorkness C; Szefler SJ; Teague WG; Thyne S; Martinez FD; JAMA 2015 Nov 17

Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis.
Chmiel JF; Konstan MW; Accurso FJ; Lymp J; Mayer-Hamblett N; VanDevanter DR; Rose LM; Ramsey BW; Assessment of Induced Sputum in Cystic Fibrosis Study Group.; Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2015 Apr 11

Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA; Annals of the American Thoracic Society 2014 Sep

Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.
Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA; Annals of the American Thoracic Society 2014 Oct

Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial.
Castro M; King TS; Kunselman SJ; Cabana MD; Denlinger L; Holguin F; Kazani SD; Moore WC; Moy J; Sorkness CA; Avila P; Bacharier LB; Bleecker E; Boushey HA; Chmiel J; Fitzpatrick AM; Gentile D; Hundal M; Israel E; Kraft M; Krishnan JA; LaForce C; Lazarus SC; Lemanske R; Lugogo N; Martin RJ; Mauger DT; Naureckas E; Peters SP; Phipatanakul W; Que LG; Sheshadri A; Smith L; Solway J; Sullivan-Vedder L; Sumino K; Wechsler ME; Wenzel S; White SR; Sutherland ER; National Heart, Lung, and Blood Institute’s AsthmaNet.; JAMA 2014 May

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
Nick JA; Moskowitz SM; Chmiel JF; Forssén AV; Kim SH; Saavedra MT; Saiman L; Taylor-Cousar JL; Nichols DP; Annals of the American Thoracic Society 2014 Mar

Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE; KB001 Study Group.; Pediatric pulmonology 2013 Sep 9

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
Busse WW; Morgan WJ; Gergen PJ; Mitchell HE; Gern JE; Liu AH; Gruchalla RS; Kattan M; Teach SJ; Pongracic JA; Chmiel JF; Steinbach SF; Calatroni A; Togias A; Thompson KM; Szefler SJ; Sorkness CA; The New England journal of medicine 2011 Mar 17

Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice.
Chmiel JF; Konstan MW; Saadane A; Krenicky JE; Lester Kirchner H; Berger M; American journal of respiratory and critical care medicine 2002 Apr 15

IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice.
Chmiel JF; Konstan MW; Knesebeck JE; Hilliard JB; Bonfield TL; Dawson DV; Berger M; American journal of respiratory and critical care medicine 1999 Dec
Professional Organizations

American Academy of Pediatrics

American College of Chest Physicians

American Pediatric Society

American Thoracic Society

Society for Pediatric Research
Board Certifications

American Board of Pediatrics - Pediatric Pulmonology

American Board of Pediatrics - Pediatrics
Clinical Interests

Dr. Chmiel sees general pulmonology patients and patients with cystic fibrosis or asthma. He also performs bronchoscopies for a variety of respiratory conditions.

Looking for patient care?

To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.

Find a doctor